<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958278</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-GREEN ( 29BRC21.0078)</org_study_id>
    <nct_id>NCT04958278</nct_id>
  </id_info>
  <brief_title>Pelvic Sentinel Node Detection Using Indocyanine Green Learning Curve</brief_title>
  <acronym>ENDO-GREEN</acronym>
  <official_title>Pelvic Sentinel Node According to SHREC-trial for the Application of the 2021 European Recommendations for Lymph Node Staging Strategy in Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to ESGO-ESTRO-ESMO guidelines, pelvic Sentinel lymph node detection is suitable for&#xD;
      lymph node staging in endometrial carcinoma of the uteri.&#xD;
&#xD;
      Nonetheless, a learning curve is mandatory to ensure the surgical quality of the sampling.&#xD;
&#xD;
      The aim of the study is to assess the success of sentinel lymph node detection according to&#xD;
      SHREC-Trial surgical strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      According to ESGO-ESTRO-ESMO guidelines, pelvic Sentinel lymph node detection is suitable for&#xD;
      lymph node staging in endometrial carcinoma of the uteri.&#xD;
&#xD;
      The aim of the study is to assess the success of sentinel lymph node detection according to&#xD;
      SHREC-Trial surgical strategy.&#xD;
&#xD;
      Patients and Method:&#xD;
&#xD;
      All patients presenting with early FIGO stage and low, intermediate, high intermediate or&#xD;
      high risk endometrial carcinoma will be prospectively enrolled.&#xD;
&#xD;
      Sentinel lymph node mapping will be performed using laparoscopic approach and cervical&#xD;
      Indocyanine Green injection.&#xD;
&#xD;
      Based on the surgical algorithm for detection of pelvic sentinel lymph node in endometrial&#xD;
      cancer from Persson and coll., we designed a study with a target of 70% to 90% of bilateral&#xD;
      detection rate .&#xD;
&#xD;
      Thirty patients will be included over 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bilateral node detection rates</measure>
    <time_frame>Day 0 (during surgery)</time_frame>
    <description>target = 70% to 90%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sentinel nodes</measure>
    <time_frame>Day 0 (during surgery)</time_frame>
    <description>number of sentinel nodes collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage operations in case of GS failure</measure>
    <time_frame>Day 0 (during surgery)</time_frame>
    <description>Number of salvage operations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Day 30</time_frame>
    <description>Per and post operative adverse events according to Clavine Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>factors for detection failure</measure>
    <time_frame>Day 0 (during surgery)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endometrial Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        30 patients over 18 months total duration of the study 20 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Letter of non objection Endometrial carcinoma Stage FIGO I-II whatever the histological&#xD;
        subtype. ESGO-ESMO-ESTRO 2021 risk classification : low, intermediate, high intermediate,&#xD;
        high Laparoscopic approach.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participation refusal Medical contraindication to laparoscopic approach. Stage FIGO &gt; II&#xD;
        Suspected Indocyanine Green allergy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-François DUPRE, MD</last_name>
    <phone>+33 2 98 22 37 59</phone>
    <email>pierre-françois.dupre@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-François DUPRE</last_name>
      <email>pierre-francois.dupre@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning 18 month and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

